Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
Nature|April 10, 2015
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Marina Caskey, Florian Klein, Julio C C Lorenzi, et al.Archives of Internal Medicine|March 10, 2010
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years, Rebecca Lodwick, Dominique Costagliola, et al.The Journal of Infectious Diseases|November 5, 2016
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)Roy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.Annals of Internal Medicine|August 23, 2017
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized TrialRoy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.Nature Medicine|September 28, 2018
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individualsYotam Bar-On, Henning Gruell, Till Schoofs, et al.Nature|June 25, 2016
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionJohannes F Scheid, Joshua A Horwitz, Yotam Bar-On, et al.Nature Medicine|January 17, 2017
Antibody 10-1074 suppresses viremia in HIV-1-infected individualsMarina Caskey, Till Schoofs, Henning Gruell, et al.Nature|September 28, 2018
Combination therapy with anti-HIV-1 antibodies maintains viral suppressionPilar Mendoza, Henning Gruell, Lilian Nogueira, et al.Annals of Internal Medicine|September 30, 2024
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons LearnedRoy M Gulick, Alice K Pau, Eric Daar, et al.Pageof 21